Nina Mian

Executive Director

AstraZeneca

Artificial Intelligence

Healthcare & Wellness

About Me

Nina is Executive Director and Head of Data Science & Advanced Analytics at AstraZeneca. She is proud to lead an exceptional multidisciplinary team dedicated to leveraging data science to drive strategic decision-making and innovation. Under Nina's leadership, the team has successfully implemented data-driven initiatives that have significantly improved operational efficiency and scientific impact, accelerating the delivery of life-changing medicines to patients. She is energized by ambitious challenges that push the boundaries of what is technically and organizationally possible, while creating a clear path to meaningful impact. Her career spans across areas including bioinformatics, knowledge engineering, real-world evidence, and learning & development. She has also held positions that foster innovation and support start-ups. Nina holds degrees in Biochemistry, Bioinformatics, and a MBA from Manchester Business School, UK.

Hear My Insights

AI-Powered Drug Innovation: From Discovery to Development

AI-Powered Drug Innovation: From Discovery to Development The traditional journey of drug discovery and development is long, expensive, and fraught with uncertainty. Today, artificial intelligence is transforming this paradigm, offering the potential to significantly compress timelines across the entire spectrum, from initial target identification through preclinical studies and clinical trials. By enabling sophisticated modeling of biological systems and patient responses with exceptional precision, AI is not only accelerating the identification of promising drug candidates but also optimizing their development pathways. This session will explore what breakthroughs are already reshaping the field—and which are just around the corner. What are the strategic and regulatory hurdles to integrating these tools into an industry built on rigorous validation? And how can we harness the full promise of AI while safeguarding the trust, safety, and ethics that underpin medical innovation?